Glutamate-GABA Circuits and Muscarinic Drugs in Psychosis
The article proposes that psychosis may stem from an imbalance in upstream glutamate-GABA circuits, with dopamine abnormalities occurring downstream. It notes that muscarinic medications can reduce symptoms and improve cognitive function. This framework challenges the traditional dopamine-centered explanation.
This account places glutamate-GABA signaling upstream in psychosis, suggesting dopamine changes may occur later in the causal chain. That reframes dopamine as a downstream feature rather than the central origin. It also points to muscarinic drugs as a possible route for easing symptoms and supporting cognition. Together, these ideas offer an alternative to explanations centered primarily on dopamine, though the summary presents them as a proposed framework rather than a settled finding.
If this framework gains attention, it could affect people with psychosis, their families, and clinicians by encouraging broader thinking about causes and treatments. Muscarinic approaches may be discussed as potential options for symptoms and cognition, while dopamine-based models could remain important. Researchers might reassess priorities, and patients may encounter new hope or uncertainty. These possible shifts would depend on further evidence and should not be treated as guaranteed outcomes.